Roche reported negative results Monday from a pair of clinical trials investigating an antibody treatment for people with early-stage Alzheimer’s disease — another setback for the Swiss pharma giant’s decades-long effort to develop medicines against the memory-destroying disease.
The drug, called gantenerumab, slowed the rate of cognitive and functional decline compared to a placebo by 8% and 6%, respectively — not enough to meet the primary goal of the two studies of just under 2,000 patients with early-stage Alzheimer’s, Roche said in a press release.
Detailed results from the studies will be presented at an Alzheimer’s research meeting on Nov. 30.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect